智通财经APP获悉，康希诺生物(06185)盘中涨超10%，截至发稿，涨9.38%，报33.25港元，成交额4845.1万港元。
消息面上，康希诺生物公布第一季度报告，按中国会计准则，实现营业收入1.37亿人民币，同比增加20%。亏损由上年同期1.7亿，大幅收窄至1155万元。曼海欣作为中国市场上唯一的四价流脑结合疫苗，市场占有率不断提升，促使本期实现营业收入1.37亿元，同比增长20.02%。
中信建投此前指出，康希诺生物2024年业绩符合预期。公司主营产品MCV系列产品持续放量，销售显著增长；公司持续加强费用管控，提升经营效率，叠加23年同期影响利润端的不利因素出清，全年实现大幅减亏。2025年，主营产品销售预计持续增长，MCV4扩龄及PCV13i有望获批，贡献业绩新增量；各项费用率有望继续降低，推动经营状况持续改善。公司后续在研管线丰富，商业化前景可期；国际化业务积极推进，期待后续进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.